Daily Stock Analysis, BPMC, Blueprint Medicines Corp, priceseries

Blueprint Medicines Corp. Daily Stock Analysis
Stock Information
Open
41.22
Close
41.01
High
41.56
Low
40.44
Previous Close
41.04
Daily Price Gain
-0.03
YTD High
42.42
YTD High Date
Mar 15, 2017
YTD Low
27.83
YTD Low Date
Jan 3, 2017
YTD Price Change
12.06
YTD Gain
41.66%
52 Week High
42.42
52 Week High Date
Mar 15, 2017
52 Week Low
13.27
52 Week Low Date
May 6, 2016
52 Week Price Change
24.57
52 Week Gain
149.45%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Nov 25. 2015
21.56
Dec 9. 2015
23.23
9 Trading Days
7.73%
Link
LONG
Mar 14. 2016
17.79
Mar 15. 2016
18.90
1 Trading Days
6.21%
Link
LONG
Mar 29. 2016
16.96
Apr 14. 2016
18.98
12 Trading Days
11.91%
Link
LONG
May 16. 2016
15.98
Jun 10. 2016
19.50
18 Trading Days
22.02%
Link
LONG
Jun 29. 2016
19.06
Jul 13. 2016
20.41
9 Trading Days
7.07%
Link
LONG
Aug 3. 2016
21.78
Sep 2. 2016
27.46
22 Trading Days
26.09%
Link
LONG
Nov 9. 2016
31.65
Nov 28. 2016
35.98
12 Trading Days
13.69%
Link
LONG
Jan 3. 2017
28.95
Feb 13. 2017
34.51
28 Trading Days
19.19%
Link
Company Information
Stock Symbol
BPMC
Exchange
NasdaqGS
Company URL
http://www.blueprintmedicines.com
Company Phone
617-374-7580
CEO
Jeffrey W. Albers
Headquarters
Massachusetts
Business Address
38 SIDNEY STREET, SUITE 200, CAMBRIDGE, MA 02139
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001597264
About

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases.

Description

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and rare genetic diseases. Its lead drug candidates include BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants for patients with systemic mastocytosis, a myeloproliferative disorder of the mast cells, and defined subsets of patients with gastrointestinal stromal tumor; and BLU-554, an orally available, potent, selective, and irreversible inhibitor of the kinase FGFR4. It is also developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that can become abnormally activated by mutations or translocations; and RET resistant mutants that would arise from treatment with first generation therapies, as well as candidates as inhibitors of neurotrophic tyrosine receptor kinase (NTRK) and predicted NTRK resistant mutants. In addition, the company is developing programs that target oncology and rare genetic diseases. The company has research, development, and commercialization agreement with Alexion Pharma Holding to research, develop, and commercialize drug candidates for an undisclosed activated kinase target, which is the cause of a rare genetic disease. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.